Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...
A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...
A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...
Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the ...
COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
Zacks Investment Research on MSN
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
Vertex Pharmaceuticals Incorporated’s VRTX third-quarter 2025 results were strong as it beat estimates for both earnings and ...
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.
Regarding market potential, I see it following an exponential curve, with forecasts indicating that by 2030, gene therapies and genetic corrections will become more widely available, potentially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback